Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
Clinical and Translational Oncology, 07/23/2012
Gomez–Martin C et al. – A moderate incidence of Hand–foot syndrome (HFS) was reported in patients treated with capecitabine, which generally presented late and required dose reduction in <1/3 of patients. The results suggest that capecitabine may be useful in combination with standard fluorouracil–based regimens in patients with advanced and/or metastatic gastric cancer with favourable safety profile.